APO Research
Talk to an analyst

APO RESEARCH · REPORT

Interleukin-17 Inhibitors

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Interleukin-17 Inhibitors Industry Growth and Trends Forecast to 2032

28 December 202596 pages

Choose your research edition.

Industry ResearchInterleukin-17 Inhibitors Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Interleukin-17 Inhibitors Industry Growth and Trends Forecast to 203296 pages · $3,450 USDMarket StructureGlobal Interleukin-17 Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Interleukin-17 Inhibitors Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Interleukin-17 Inhibitors Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Interleukin-17 Inhibitors market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Interleukin-17 Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Interleukin-17 Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Interleukin-17 Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Interleukin-17 Inhibitors include Chongqing Genrix Biopharmaceutical, Akesobio, Jiangsu Hengrui Medicine, UCB, Novartis, Eli Lilly and Co., DICE Therapeutics and AstraZeneca, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Interleukin-17 Inhibitors market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Interleukin-17 Inhibitors market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Interleukin-17 Inhibitors market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Interleukin-17 Inhibitors.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Interleukin-17 Inhibitors market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Interleukin-17 Inhibitors Market by Company

Chongqing Genrix Biopharmaceutical

Akesobio

Jiangsu Hengrui Medicine

UCB

Novartis

Eli Lilly and Co.

DICE Therapeutics

AstraZeneca

Interleukin-17 Inhibitors Segment by Type

Oral

Injection

Interleukin-17 Inhibitors Segment by Application

Hospital

Clinic

Other

Interleukin-17 Inhibitors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Interleukin-17 Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Interleukin-17 Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Interleukin-17 Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Interleukin-17 Inhibitors manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Interleukin-17 Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Oral Table 2. Major Company of Injection Table 3. Global Interleukin-17 Inhibitors Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Interleukin-17 Inhibitors Sales by Type (2021-2026) & (K Units) Table 5. Global Interleukin-17 Inhibitors Sales Market Share in Volume by Type (2021-2026) Table 6. Global Interleukin-17 Inhibitors Sales by Type (2021-2026) & (US$ Million) Table 7. Global Interleukin-17 Inhibitors Sales Market Share in Value by Type (2021-2026) Table 8. Global Interleukin-17 Inhibitors Price by Type (2021-2026) & (US$/Unit) Table 9. Global Interleukin-17 Inhibitors Sales by Type (2027-2032) & (K Units) Table 10. Global Interleukin-17 Inhibitors Sales Market Share in Volume by Type (2027-2032) Table 11. Global Interleukin-17 Inhibitors Sales by Type (2027-2032) & (US$ Million) Table 12. Global Interleukin-17 Inhibitors Sales Market Share in Value by Type (2027-2032) Table 13. Global Interleukin-17 Inhibitors Price by Type (2027-2032) & (US$/Unit) Table 14. North America Interleukin-17 Inhibitors Sales by Type (2021-2026) & (K Units) Table 15. North America Interleukin-17 Inhibitors Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Interleukin-17 Inhibitors Sales by Type (2021-2026) & (K Units) Table 17. Europe Interleukin-17 Inhibitors Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Interleukin-17 Inhibitors Sales by Type (2021-2026) & (K Units) Table 19. Asia-Pacific Interleukin-17 Inhibitors Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Interleukin-17 Inhibitors Sales by Type (2021-2026) & (K Units) Table 21. Latin America Interleukin-17 Inhibitors Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Interleukin-17 Inhibitors Sales by Type (2021-2026) & (K Units) Table 23. Middle East and Africa Interleukin-17 Inhibitors Sales by Type (2021-2026) & (US$ Million) Table 24. Interleukin-17 Inhibitors Industry Trends Table 25. Interleukin-17 Inhibitors Industry Drivers Table 26. Interleukin-17 Inhibitors Industry Opportunities and Challenges Table 27. Interleukin-17 Inhibitors Industry Restraints Table 28. Global Interleukin-17 Inhibitors Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Interleukin-17 Inhibitors Revenue Market Share by Company (2021-2026) Table 30. Global Interleukin-17 Inhibitors Sales by Company (2021-2026) & (K Units) Table 31. Global Interleukin-17 Inhibitors Sales Share by Company (2021-2026) Table 32. Global Interleukin-17 Inhibitors Market Price by Company (2021-2026) & (US$/Unit) Table 33. Global Interleukin-17 Inhibitors Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Interleukin-17 Inhibitors Major Company Production Sites and Headquarters Table 35. Global Interleukin-17 Inhibitors Company, Product Type & Application Table 36. Global Interleukin-17 Inhibitors Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Interleukin-17 Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Interleukin-17 Inhibitors Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Interleukin-17 Inhibitors Sales by Region (2021-2026) & (K Units) Table 41. Global Interleukin-17 Inhibitors Sales Market Share in Volume by Region (2021-2026) Table 42. Global Interleukin-17 Inhibitors Sales by Region (2021-2026) & (US$ Million) Table 43. Global Interleukin-17 Inhibitors Sales Market Share in Value by Region (2021-2026) Table 44. Global Interleukin-17 Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 45. Global Interleukin-17 Inhibitors Sales by Region (2027-2032) & (K Units) Table 46. Global Interleukin-17 Inhibitors Sales Market Share in Volume by Region (2027-2032) Table 47. Global Interleukin-17 Inhibitors Sales by Region (2027-2032) & (US$ Million) Table 48. Global Interleukin-17 Inhibitors Sales Market Share in Value by Region (2027-2032) Table 49. Global Interleukin-17 Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 50. Global Interleukin-17 Inhibitors Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Interleukin-17 Inhibitors Sales by Application (2021-2026) & (K Units) Table 52. Global Interleukin-17 Inhibitors Sales Market Share in Volume by Application (2021-2026) Table 53. Global Interleukin-17 Inhibitors Sales by Application (2021-2026) & (US$ Million) Table 54. Global Interleukin-17 Inhibitors Sales Market Share in Value by Application (2021-2026) Table 55. Global Interleukin-17 Inhibitors Price by Application (2021-2026) & (US$/Unit) Table 56. Global Interleukin-17 Inhibitors Sales by Application (2027-2032) & (K Units) Table 57. Global Interleukin-17 Inhibitors Sales Market Share in Volume by Application (2027-2032) Table 58. Global Interleukin-17 Inhibitors Sales by Application (2027-2032) & (US$ Million) Table 59. Global Interleukin-17 Inhibitors Sales Market Share in Value by Application (2027-2032) Table 60. Global Interleukin-17 Inhibitors Price by Application (2027-2032) & (US$/Unit) Table 61. North America Interleukin-17 Inhibitors Sales by Application (2021-2026) & (K Units) Table 62. North America Interleukin-17 Inhibitors Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Interleukin-17 Inhibitors Sales by Application (2021-2026) & (K Units) Table 64. Europe Interleukin-17 Inhibitors Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Interleukin-17 Inhibitors Sales by Application (2021-2026) & (K Units) Table 66. Asia-Pacific Interleukin-17 Inhibitors Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Interleukin-17 Inhibitors Sales by Application (2021-2026) & (K Units) Table 68. Latin America Interleukin-17 Inhibitors Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Interleukin-17 Inhibitors Sales by Application (2021-2026) & (K Units) Table 70. Middle East and Africa Interleukin-17 Inhibitors Sales by Application (2021-2026) & (US$ Million) Table 71. Chongqing Genrix Biopharmaceutical Company Information Table 72. Chongqing Genrix Biopharmaceutical Business Overview Table 73. Chongqing Genrix Biopharmaceutical Interleukin-17 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Chongqing Genrix Biopharmaceutical Interleukin-17 Inhibitors Product Portfolio Table 75. Chongqing Genrix Biopharmaceutical Recent Development Table 76. Akesobio Company Information Table 77. Akesobio Business Overview Table 78. Akesobio Interleukin-17 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Akesobio Interleukin-17 Inhibitors Product Portfolio Table 80. Akesobio Recent Development Table 81. Jiangsu Hengrui Medicine Company Information Table 82. Jiangsu Hengrui Medicine Business Overview Table 83. Jiangsu Hengrui Medicine Interleukin-17 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Jiangsu Hengrui Medicine Interleukin-17 Inhibitors Product Portfolio Table 85. Jiangsu Hengrui Medicine Recent Development Table 86. UCB Company Information Table 87. UCB Business Overview Table 88. UCB Interleukin-17 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. UCB Interleukin-17 Inhibitors Product Portfolio Table 90. UCB Recent Development Table 91. Novartis Company Information Table 92. Novartis Business Overview Table 93. Novartis Interleukin-17 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Novartis Interleukin-17 Inhibitors Product Portfolio Table 95. Novartis Recent Development Table 96. Eli Lilly and Co. Company Information Table 97. Eli Lilly and Co. Business Overview Table 98. Eli Lilly and Co. Interleukin-17 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Eli Lilly and Co. Interleukin-17 Inhibitors Product Portfolio Table 100. Eli Lilly and Co. Recent Development Table 101. DICE Therapeutics Company Information Table 102. DICE Therapeutics Business Overview Table 103. DICE Therapeutics Interleukin-17 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. DICE Therapeutics Interleukin-17 Inhibitors Product Portfolio Table 105. DICE Therapeutics Recent Development Table 106. AstraZeneca Company Information Table 107. AstraZeneca Business Overview Table 108. AstraZeneca Interleukin-17 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. AstraZeneca Interleukin-17 Inhibitors Product Portfolio Table 110. AstraZeneca Recent Development Table 111. North America Interleukin-17 Inhibitors Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 112. North America Interleukin-17 Inhibitors Sales by Country (2021-2026) & (K Units) Table 113. North America Interleukin-17 Inhibitors Sales Market Share by Country (2021-2026) Table 114. North America Interleukin-17 Inhibitors Sales Forecast by Country (2027-2032) & (K Units) Table 115. North America Interleukin-17 Inhibitors Sales Market Share Forecast by Country (2027-2032) Table 116. North America Interleukin-17 Inhibitors Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 117. North America Interleukin-17 Inhibitors Market Size by Country (2021-2026) & (US$ Million) Table 118. North America Interleukin-17 Inhibitors Market Share by Country (2021-2026) Table 119. North America Interleukin-17 Inhibitors Market Size Forecast by Country (2027-2032) & (US$ Million) Table 120. North America Interleukin-17 Inhibitors Market Share Forecast by Country (2027-2032) Table 121. Europe Interleukin-17 Inhibitors Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 122. Europe Interleukin-17 Inhibitors Sales by Country (2021-2026) & (K Units) Table 123. Europe Interleukin-17 Inhibitors Sales Market Share by Country (2021-2026) Table 124. Europe Interleukin-17 Inhibitors Sales Forecast by Country (2027-2032) & (K Units) Table 125. Europe Interleukin-17 Inhibitors Sales Market Share Forecast by Country (2027-2032) Table 126. Europe Interleukin-17 Inhibitors Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 127. Europe Interleukin-17 Inhibitors Market Size by Country (2021-2026) & (US$ Million) Table 128. Europe Interleukin-17 Inhibitors Market Share by Country (2021-2026) Table 129. Europe Interleukin-17 Inhibitors Market Size Forecast by Country (2027-2032) & (US$ Million) Table 130. Europe Interleukin-17 Inhibitors Market Share Forecast by Country (2027-2032) Table 131. Asia-Pacific Interleukin-17 Inhibitors Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 132. Asia-Pacific Interleukin-17 Inhibitors Sales by Country (2021-2026) & (K Units) Table 133. Asia-Pacific Interleukin-17 Inhibitors Sales Market Share by Country (2021-2026) Table 134. Asia-Pacific Interleukin-17 Inhibitors Sales Forecast by Country (2027-2032) & (K Units) Table 135. Asia-Pacific Interleukin-17 Inhibitors Sales Market Share Forecast by Country (2027-2032) Table 136. Asia-Pacific Interleukin-17 Inhibitors Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 137. Asia-Pacific Interleukin-17 Inhibitors Market Size by Country (2021-2026) & (US$ Million) Table 138. Asia-Pacific Interleukin-17 Inhibitors Market Share by Country (2021-2026) Table 139. Asia-Pacific Interleukin-17 Inhibitors Market Size Forecast by Country (2027-2032) & (US$ Million) Table 140. Asia-Pacific Interleukin-17 Inhibitors Market Share Forecast by Country (2027-2032) Table 141. Latin America Interleukin-17 Inhibitors Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 142. Latin America Interleukin-17 Inhibitors Sales by Country (2021-2026) & (K Units) Table 143. Latin America Interleukin-17 Inhibitors Sales Market Share by Country (2021-2026) Table 144. Latin America Interleukin-17 Inhibitors Sales Forecast by Country (2027-2032) & (K Units) Table 145. Latin America Interleukin-17 Inhibitors Sales Market Share Forecast by Country (2027-2032) Table 146. Latin America Interleukin-17 Inhibitors Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 147. Latin America Interleukin-17 Inhibitors Market Size by Country (2021-2026) & (US$ Million) Table 148. Latin America Interleukin-17 Inhibitors Market Share by Country (2021-2026) Table 149. Latin America Interleukin-17 Inhibitors Market Size Forecast by Country (2027-2032) & (US$ Million) Table 150. Latin America Interleukin-17 Inhibitors Market Share Forecast by Country (2027-2032) Table 151. Middle East and Africa Interleukin-17 Inhibitors Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 152. Middle East and Africa Interleukin-17 Inhibitors Sales by Country (2021-2026) & (K Units) Table 153. Middle East and Africa Interleukin-17 Inhibitors Sales Market Share by Country (2021-2026) Table 154. Middle East and Africa Interleukin-17 Inhibitors Sales Forecast by Country (2027-2032) & (K Units) Table 155. Middle East and Africa Interleukin-17 Inhibitors Sales Market Share Forecast by Country (2027-2032) Table 156. Middle East and Africa Interleukin-17 Inhibitors Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 157. Middle East and Africa Interleukin-17 Inhibitors Market Size by Country (2021-2026) & (US$ Million) Table 158. Middle East and Africa Interleukin-17 Inhibitors Market Share by Country (2021-2026) Table 159. Middle East and Africa Interleukin-17 Inhibitors Market Size Forecast by Country (2027-2032) & (US$ Million) Table 160. Middle East and Africa Interleukin-17 Inhibitors Market Share Forecast by Country (2027-2032) Table 161. Key Raw Materials Table 162. Raw Materials Key Suppliers Table 163. Interleukin-17 Inhibitors Distributors List Table 164. Interleukin-17 Inhibitors Customers List Table 165. Research Programs/Design for This Report Table 166. Authors List of This Report Table 167. Secondary Sources Table 168. Primary Sources List of Figures Figure 1. Interleukin-17 Inhibitors Image Figure 2. Global Interleukin-17 Inhibitors Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Interleukin-17 Inhibitors Market Size (2021-2032) & (US$ Million) Figure 4. Global Interleukin-17 Inhibitors Sales (2021-2032) & (K Units) Figure 5. Oral Image Figure 6. Global Oral Sales YoY Growth (2021-2032) & (K Units) Figure 7. Injection Image Figure 8. Global Injection Sales YoY Growth (2021-2032) & (K Units) Figure 9. Global Interleukin-17 Inhibitors Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Interleukin-17 Inhibitors Market Share by Type 2025 VS 2032 Figure 11. North America Interleukin-17 Inhibitors Sales Market Share in Volume by Type in 2025 Figure 12. North America Interleukin-17 Inhibitors Sales Market Share in Value by Type in 2025 Figure 13. Europe Interleukin-17 Inhibitors Sales Market Share in Volume by Type in 2025 Figure 14. Europe Interleukin-17 Inhibitors Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Interleukin-17 Inhibitors Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Interleukin-17 Inhibitors Sales Market Share in Value by Type in 2025 Figure 17. Latin America Interleukin-17 Inhibitors Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Interleukin-17 Inhibitors Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Interleukin-17 Inhibitors Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Interleukin-17 Inhibitors Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Interleukin-17 Inhibitors Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Hospital Image Figure 24. Global Hospital Sales YoY Growth (2021-2032) & (K Units) Figure 25. Clinic Image Figure 26. Global Clinic Sales YoY Growth (2021-2032) & (K Units) Figure 27. Other Image Figure 28. Global Other Sales YoY Growth (2021-2032) & (K Units) Figure 29. Global Interleukin-17 Inhibitors Market Size Overview by Application (2021-2032) & (US$ Million) Figure 30. Global Interleukin-17 Inhibitors Market Share by Application 2025 VS 2032 Figure 31. North America Interleukin-17 Inhibitors Sales Market Share in Volume by Application in 2025 Figure 32. North America Interleukin-17 Inhibitors Sales Market Share in Value by Application in 2025 Figure 33. Europe Interleukin-17 Inhibitors Sales Market Share in Volume by Application in 2025 Figure 34. Europe Interleukin-17 Inhibitors Sales Market Share in Value by Application in 2025 Figure 35. Asia-Pacific Interleukin-17 Inhibitors Sales Market Share in Volume by Application in 2025 Figure 36. Asia-Pacific Interleukin-17 Inhibitors Sales Market Share in Value by Application in 2025 Figure 37. Latin America Interleukin-17 Inhibitors Sales Market Share in Volume by Application in 2025 Figure 38. Latin America Interleukin-17 Inhibitors Sales Market Share in Value by Application in 2025 Figure 39. Middle East and Africa Interleukin-17 Inhibitors Sales Market Share in Volume by Application in 2025 Figure 40. Middle East and Africa Interleukin-17 Inhibitors Sales Market Share in Value by Application in 2025 Figure 41. North America Interleukin-17 Inhibitors Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 42. North America Interleukin-17 Inhibitors Sales Share by Country: 2021 VS 2025 VS 2032 Figure 43. North America Interleukin-17 Inhibitors Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 44. North America Interleukin-17 Inhibitors Market Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Interleukin-17 Inhibitors Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 46. Europe Interleukin-17 Inhibitors Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Interleukin-17 Inhibitors Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Europe Interleukin-17 Inhibitors Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Asia-Pacific Interleukin-17 Inhibitors Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 50. Asia-Pacific Interleukin-17 Inhibitors Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Interleukin-17 Inhibitors Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Asia-Pacific Interleukin-17 Inhibitors Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Interleukin-17 Inhibitors Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 54. Latin America Interleukin-17 Inhibitors Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Interleukin-17 Inhibitors Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Latin America Interleukin-17 Inhibitors Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Middle East and Africa Interleukin-17 Inhibitors Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 58. Middle East and Africa Interleukin-17 Inhibitors Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Interleukin-17 Inhibitors Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Middle East and Africa Interleukin-17 Inhibitors Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Interleukin-17 Inhibitors Value Chain Figure 62. Key Raw Materials Price Figure 63. Manufacturing Cost Structure Figure 64. Interleukin-17 Inhibitors Production Mode & Process Figure 65. Direct Comparison with Distribution Share Figure 66. Distributors Profiles Figure 67. Years Considered Figure 68. Research Process Figure 69. Key Executives Interviewed

Scope & coverage.

Types
  • Oral
  • Injection
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Chongqing Genrix Biopharmaceutical
  • Akesobio
  • Jiangsu Hengrui Medicine
  • UCB
  • Novartis
  • Eli Lilly and Co.
  • DICE Therapeutics
  • AstraZeneca

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Interleukin-17 Inhibitors Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Interleukin-17 Inhibitors Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Interleukin-17 Inhibitors Market by Type
  6. 1.3.1 Oral
  7. 1.3.2 Injection
  8. 1.4 Global Interleukin-17 Inhibitors Market Size by Type
  9. 1.4.1 Global Interleukin-17 Inhibitors Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Interleukin-17 Inhibitors Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Interleukin-17 Inhibitors Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Interleukin-17 Inhibitors Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Interleukin-17 Inhibitors Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Interleukin-17 Inhibitors Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Interleukin-17 Inhibitors Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Interleukin-17 Inhibitors Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Interleukin-17 Inhibitors Industry Trends
  2. 2.2 Interleukin-17 Inhibitors Industry Drivers
  3. 2.3 Interleukin-17 Inhibitors Industry Opportunities and Challenges
  4. 2.4 Interleukin-17 Inhibitors Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Interleukin-17 Inhibitors Revenue (2021-2026)
  2. 3.2 Global Top Players by Interleukin-17 Inhibitors Sales (2021-2026)
  3. 3.3 Global Top Players by Interleukin-17 Inhibitors Price (2021-2026)
  4. 3.4 Global Interleukin-17 Inhibitors Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Interleukin-17 Inhibitors Major Company Production Sites & Headquarters
  6. 3.6 Global Interleukin-17 Inhibitors Company, Product Type & Application
  7. 3.7 Global Interleukin-17 Inhibitors Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Interleukin-17 Inhibitors Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Interleukin-17 Inhibitors Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Interleukin-17 Inhibitors Tier 1, Tier 2, and Tier 3
4 Interleukin-17 Inhibitors Regional Status and Outlook
  1. 4.1 Global Interleukin-17 Inhibitors Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Interleukin-17 Inhibitors Historic Market Size by Region
  3. 4.2.1 Global Interleukin-17 Inhibitors Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Interleukin-17 Inhibitors Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Interleukin-17 Inhibitors Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Interleukin-17 Inhibitors Forecasted Market Size by Region
  7. 4.3.1 Global Interleukin-17 Inhibitors Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Interleukin-17 Inhibitors Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Interleukin-17 Inhibitors Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Interleukin-17 Inhibitors by Application
  1. 5.1 Interleukin-17 Inhibitors Market by Application
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Other
  5. 5.2 Global Interleukin-17 Inhibitors Market Size by Application
  6. 5.2.1 Global Interleukin-17 Inhibitors Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Interleukin-17 Inhibitors Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Interleukin-17 Inhibitors Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Interleukin-17 Inhibitors Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Interleukin-17 Inhibitors Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Interleukin-17 Inhibitors Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Interleukin-17 Inhibitors Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Interleukin-17 Inhibitors Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Chongqing Genrix Biopharmaceutical
  2. 6.1.1 Chongqing Genrix Biopharmaceutical Company Information
  3. 6.1.2 Chongqing Genrix Biopharmaceutical Business Overview
  4. 6.1.3 Chongqing Genrix Biopharmaceutical Interleukin-17 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Chongqing Genrix Biopharmaceutical Interleukin-17 Inhibitors Product Portfolio
  6. 6.1.5 Chongqing Genrix Biopharmaceutical Recent Developments
  7. 6.2 Akesobio
  8. 6.2.1 Akesobio Company Information
  9. 6.2.2 Akesobio Business Overview
  10. 6.2.3 Akesobio Interleukin-17 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Akesobio Interleukin-17 Inhibitors Product Portfolio
  12. 6.2.5 Akesobio Recent Developments
  13. 6.3 Jiangsu Hengrui Medicine
  14. 6.3.1 Jiangsu Hengrui Medicine Company Information
  15. 6.3.2 Jiangsu Hengrui Medicine Business Overview
  16. 6.3.3 Jiangsu Hengrui Medicine Interleukin-17 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Jiangsu Hengrui Medicine Interleukin-17 Inhibitors Product Portfolio
  18. 6.3.5 Jiangsu Hengrui Medicine Recent Developments
  19. 6.4 UCB
  20. 6.4.1 UCB Company Information
  21. 6.4.2 UCB Business Overview
  22. 6.4.3 UCB Interleukin-17 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 UCB Interleukin-17 Inhibitors Product Portfolio
  24. 6.4.5 UCB Recent Developments
  25. 6.5 Novartis
  26. 6.5.1 Novartis Company Information
  27. 6.5.2 Novartis Business Overview
  28. 6.5.3 Novartis Interleukin-17 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Novartis Interleukin-17 Inhibitors Product Portfolio
  30. 6.5.5 Novartis Recent Developments
  31. 6.6 Eli Lilly and Co.
  32. 6.6.1 Eli Lilly and Co. Company Information
  33. 6.6.2 Eli Lilly and Co. Business Overview
  34. 6.6.3 Eli Lilly and Co. Interleukin-17 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Eli Lilly and Co. Interleukin-17 Inhibitors Product Portfolio
  36. 6.6.5 Eli Lilly and Co. Recent Developments
  37. 6.7 DICE Therapeutics
  38. 6.7.1 DICE Therapeutics Company Information
  39. 6.7.2 DICE Therapeutics Business Overview
  40. 6.7.3 DICE Therapeutics Interleukin-17 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 DICE Therapeutics Interleukin-17 Inhibitors Product Portfolio
  42. 6.7.5 DICE Therapeutics Recent Developments
  43. 6.8 AstraZeneca
  44. 6.8.1 AstraZeneca Company Information
  45. 6.8.2 AstraZeneca Business Overview
  46. 6.8.3 AstraZeneca Interleukin-17 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 AstraZeneca Interleukin-17 Inhibitors Product Portfolio
  48. 6.8.5 AstraZeneca Recent Developments
7 North America by Country
  1. 7.1 North America Interleukin-17 Inhibitors Sales by Country
  2. 7.1.1 North America Interleukin-17 Inhibitors Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Interleukin-17 Inhibitors Sales by Country (2021-2026)
  4. 7.1.3 North America Interleukin-17 Inhibitors Sales Forecast by Country (2027-2032)
  5. 7.2 North America Interleukin-17 Inhibitors Market Size by Country
  6. 7.2.1 North America Interleukin-17 Inhibitors Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Interleukin-17 Inhibitors Market Size by Country (2021-2026)
  8. 7.2.3 North America Interleukin-17 Inhibitors Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Interleukin-17 Inhibitors Sales by Country
  2. 8.1.1 Europe Interleukin-17 Inhibitors Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Interleukin-17 Inhibitors Sales by Country (2021-2026)
  4. 8.1.3 Europe Interleukin-17 Inhibitors Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Interleukin-17 Inhibitors Market Size by Country
  6. 8.2.1 Europe Interleukin-17 Inhibitors Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Interleukin-17 Inhibitors Market Size by Country (2021-2026)
  8. 8.2.3 Europe Interleukin-17 Inhibitors Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Interleukin-17 Inhibitors Sales by Country
  2. 9.1.1 Asia-Pacific Interleukin-17 Inhibitors Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Interleukin-17 Inhibitors Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Interleukin-17 Inhibitors Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Interleukin-17 Inhibitors Market Size by Country
  6. 9.2.1 Asia-Pacific Interleukin-17 Inhibitors Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Interleukin-17 Inhibitors Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Interleukin-17 Inhibitors Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Interleukin-17 Inhibitors Sales by Country
  2. 10.1.1 South America Interleukin-17 Inhibitors Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Interleukin-17 Inhibitors Sales by Country (2021-2026)
  4. 10.1.3 South America Interleukin-17 Inhibitors Sales Forecast by Country (2027-2032)
  5. 10.2 South America Interleukin-17 Inhibitors Market Size by Country
  6. 10.2.1 South America Interleukin-17 Inhibitors Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Interleukin-17 Inhibitors Market Size by Country (2021-2026)
  8. 10.2.3 South America Interleukin-17 Inhibitors Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Interleukin-17 Inhibitors Sales by Country
  2. 11.1.1 Middle East and Africa Interleukin-17 Inhibitors Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Interleukin-17 Inhibitors Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Interleukin-17 Inhibitors Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Interleukin-17 Inhibitors Market Size by Country
  6. 11.2.1 Middle East and Africa Interleukin-17 Inhibitors Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Interleukin-17 Inhibitors Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Interleukin-17 Inhibitors Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Interleukin-17 Inhibitors Value Chain Analysis
  2. 12.1.1 Interleukin-17 Inhibitors Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Interleukin-17 Inhibitors Production Mode & Process
  7. 12.2 Interleukin-17 Inhibitors Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Interleukin-17 Inhibitors Distributors
  10. 12.2.3 Interleukin-17 Inhibitors Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst